Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Hepion to highlight AI-POWR platform at AI webinar

Hepion Pharmaceuticals (NASDAQ:HEPA) will highlight its AI-POWR platform in a presentation during a webinar on March 23 entitled, “How Artificial Intelligence is Changing Drug Discovery.” The webinar is being co-hosted...

March 17, 2023

Developments

OpSens in specialty diagnostics pact with Premier for SavvyWire

OpSens (TSX:OPS; OTCQX:OPSSF) was awarded a national group purchasing agreement for interventional specialty diagnostics with Premier, a leading healthcare improvement company uniting an alliance with approximately...

March 14, 2023

Developments

Reneo reaches target enrollment in pivotal trial in primary mitochondrial myopathies

Reneo Pharmaceuticals (NASDAQ:RPHM) achieved its target enrollment of 200 patients in the pivotal STRIDE study of mavodelpar in primary mitochondrial myopathies (PMM). Topline data from the STRIDE study are expected in...

March 14, 2023

Developments

LENZ Therapeutics in $83.5-million series B financing to advance presbyopia treatments

LENZ Therapeutics raised $83.5-million in an oversubscribed Series B financing. New investor, Sectoral Asset Management, led the financing and was joined by Alpha Wave Ventures and Point 72, as well as existing...

March 7, 2023

Developments

BioStem to acquire majority of assets of Auxocell Laboratories

BioStem Technologies (OTCQB:BSEM) agreed to acquire the majority of the assets of Auxocell Laboratories, a leading solid tissue processing equipment manufacturer. The Auxocell solid tissue processing device, AC:Px, is a...

March 7, 2023

Developments

Hepion to update rencofilstat Phase 2 programs at NASH Congress

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CMO, Todd Hobbs, M.D., will be presenting, “Rencofilstat (CRV431): Update on NASH Clinical Program,” on March 3 at the 6th Global NASH Congress in London. Dr. Hobbs will be...

March 3, 2023

Developments

Hepion’s rencofilstat IP estate strengthened with new European patent

The European Patent Office granted a patent to Hepion Pharmaceuticals (NASDAQ:HEPA) covering the innovative formulation of Hepion’s lead cyclophilin inhibitor, rencofilstat. The newly granted European patent also...

March 2, 2023

Developments

FDA grants orphan drug to Aravive’s batiraxcept for pancreatic cancer

The FDA granted orphan drug designation for Aravive’s (NASDAQ:ARAV) batiraxcept for the treatment of pancreatic ductal adenocarcinoma cancer (PDAC). In a statement, Gail McIntyre, Ph.D., DABT, CEO of Aravive, said three...

March 1, 2023

Developments

Atossa doses first patient in Phase 2 breast cancer study

Atossa Therapeutics (NASDAQ:ATOS) dosed the first patient in the Phase 2 EVANGELINE non-inferiority clinical trial of Atossa’s patented selective estrogen receptor modulator, (Z)-endoxifen, and exemestane plus goserelin...

February 23, 2023

Developments

Theralase presents Phase 2 NMIBC interim data at ASCO GU

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) presented interim data from its Phase 2 (Study II) clinical study at the American Society of Clinical Oncology (ASCO) Genito Urinary Cancer Symposium via a moderated poster...

February 23, 2023

Developments

SenterCare in pact to bring aging-at-home-safely technology to Japan

Closely-held SenterCare, a member of the Trendlines Group of Israel, and Nozomi MedAlliance established an alliance to bring SenterCare’s advanced aging-at-home-safely technology to the Japanese market. SenterCare has...

February 21, 2023

Developments

IntelGenx receives USPTO notice of allowance for loxapine Orange Book eligible patent

The United States Patent and Trademark Office has granted a notice of allowance for IntelGenx’s (TSX:IGX; OTCQB:IGXT) U.S. patent application entitled, “Loxapine Film Oral Dosage Form.” The film formulation patent...

February 21, 2023

Developments

Theralase named to TSXV 2023 Venture 50

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) was named to the TSX Venture Exchange’s 2023 Venture 50, an annual ranking of top-performing companies from five industry sectors. Theralase was recognized in the clean...

February 21, 2023

Developments

Freedom Holding to acquire Maxim Group for $400-million

Freedom Holding (NASDAQ:FRHC), a multi-national financial services firm, agreed to acquire Maxim Group and its registered investment advisory affiliate, Maxim Financial Advisors, for a combination of cash and common...

February 17, 2023

Developments

iBio selects MUC16 as next immuno-oncology target program

iBio (NYSE American:IBIO) selected MUC16 as the target of its latest immuno-oncology program. MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and...

February 17, 2023

Developments

Aravive to present positive updated data at ASCO GU cancer symposium

Aravive (NASDAQ:ARAV) will present updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU)...

February 14, 2023

Developments

Cardiology imaging study urges use of intravascular imaging for PCI guidance

A new review from the American College of Cardiology’s Interventional Council strongly suggests that intracoronary imaging should now be a routine part of clinical practice, as it can be used to assess the lesion prior...

February 14, 2023

Developments

Cognition completes enrollment in Phase 2 SEQUEL study in AD

Cognition Therapeutics (NASDAQ:CGTX) completed enrollment in the randomized, double-blind Phase 2 SEQUEL study of its CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease. The study was designed to assess...

February 9, 2023

Developments

SeaStar Medical to begin AKI device study to reduce hyperinflammation in adults

The FDA approved SeaStar Medical’s (NASDAQ:ICU) investigational device exemption application to conduct a pivotal study evaluating the effectiveness of its Selective Cytopheretic Device (SCD) in reducing...

February 9, 2023

Developments

Abbott to acquire Cardiovascular Systems for $890-million

Abbott (NYSE:ABT) agreed to acquire Cardiovascular Systems, Inc. (NASDAQ:CSII) for $20 a share or approximately $890-million. Cardiovascular Systems is a leader in devices for atherectomy, a minimally invasive treatment...

February 9, 2023

Developments

IntelGenx in research collaboration with renowned neurologist for Montelukast VersaFilm in PD

IntelGenx (TSX:IGX; OTCQB:IGXT) announced a research collaboration with Per Svenningsson, M.D., Ph.D., of the Karolinska Institute, to plan and conduct a multicentre, randomized, double-blind, placebo-controlled...

February 9, 2023

Developments

NeuroSense cleared in Germany to enroll patients in Phase 2b ALS trial

Germany’s Federal Institute for Drugs and Medical Devices approved NeuroSense Therapeutics’ (NASDAQ:NRSN) clinical trial application to enroll patients in PARADIGM, a Phase 2b study of its lead combination drug...

February 8, 2023

Hepion to highlight AI-POWR platform at AI webinar

OpSens in specialty diagnostics pact with Premier for SavvyWire

Reneo reaches target enrollment in pivotal trial in primary mitochondrial myopathies

LENZ Therapeutics in $83.5-million series B financing to advance presbyopia treatments

BioStem to acquire majority of assets of Auxocell Laboratories

Hepion to update rencofilstat Phase 2 programs at NASH Congress

Hepion’s rencofilstat IP estate strengthened with new European patent

FDA grants orphan drug to Aravive’s batiraxcept for pancreatic cancer

Atossa doses first patient in Phase 2 breast cancer study

Theralase presents Phase 2 NMIBC interim data at ASCO GU

SenterCare in pact to bring aging-at-home-safely technology to Japan

IntelGenx receives USPTO notice of allowance for loxapine Orange Book eligible patent

Theralase named to TSXV 2023 Venture 50

Freedom Holding to acquire Maxim Group for $400-million

iBio selects MUC16 as next immuno-oncology target program

Aravive to present positive updated data at ASCO GU cancer symposium

Cardiology imaging study urges use of intravascular imaging for PCI guidance

Cognition completes enrollment in Phase 2 SEQUEL study in AD

SeaStar Medical to begin AKI device study to reduce hyperinflammation in adults

Abbott to acquire Cardiovascular Systems for $890-million

IntelGenx in research collaboration with renowned neurologist for Montelukast VersaFilm in PD

NeuroSense cleared in Germany to enroll patients in Phase 2b ALS trial

General

More